RIDGEFIELD, Conn., June 18, 2012 /PRNewswire/ -- A new retrospective sub-analysis of the RE-LY?? trial suggested similar rates of peri-procedural bleeding and thromboembolic complications, such as a stroke or systemic embolism, in non-valvular atrial fibrillation (NVAF) patients undergoing a surgical or invasive procedure treated with Pradaxa?? (dabigatran etexilate mesylate) capsules 150mg taken